Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High Following Analyst Upgrade

Gilead Sciences, Inc. (NASDAQ:GILD) shares reached a new 52-week high on Monday after Leerink Partners raised their price target on the stock from $114.00 to $146.00. Leerink Partners currently has an outperform rating on the stock. Gilead Sciences traded as high as $142.20 and last traded at $141.53, with a volume of 8928 shares trading hands. The stock had previously closed at $141.95.

A number of other research firms also recently issued reports on GILD. Truist Financial lifted their price objective on Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. UBS Group lifted their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Wolfe Research upped their target price on shares of Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $136.73.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 257,397 shares of company stock valued at $33,385,512. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently bought and sold shares of the business. Personal CFO Solutions LLC raised its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares in the last quarter. Moss Adams Wealth Advisors LLC raised its stake in Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after buying an additional 76 shares during the last quarter. Valued Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 12.5% during the fourth quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 79 shares during the last quarter. SOA Wealth Advisors LLC. boosted its stake in Gilead Sciences by 8.7% in the 4th quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 81 shares in the last quarter. Finally, Trivium Point Advisory LLC increased its stake in Gilead Sciences by 1.1% during the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after purchasing an additional 83 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.6%

The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company’s 50 day moving average price is $125.36 and its 200 day moving average price is $119.73. The firm has a market capitalization of $177.22 billion, a price-to-earnings ratio of 21.76, a P/E/G ratio of 0.74 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.02 EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.